Multiple Sclerosis Headlines

Presence of CHI3L1 and NFL in CSF Predicts Risk for Demyelinating Syndromes

Presence of CHI3L1 and NFL in CSF Predicts Risk for Demyelinating Syndromes

Investigators assess the diagnostic value of 2 CSF biomarkers to distinguish pediatric acquired demyelinating syndromes from non-acquired demyelinating syndromes.

FDA Accepts NDA Resubmission for Oral Cladribine in Relapsing MS

FDA Accepts NDA Resubmission for Oral Cladribine in Relapsing MS

The NDA resubmission is in response to the FDA's Complete Response Letter issued in 2011 which requested an improved understanding of the safety risks and overall benefit-risk profile.

Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis

Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis

The combination of genetics and exposure to organic solvents in paints and varnishes increases the risk of multiple sclerosis.

Dynamics of Brain Volume Loss Vary With MS Progression

Dynamics of Brain Volume Loss Vary With MS Progression

Brain volume loss has nonlinear dynamics and limited reproducibility as a marker of therapeutic response in multiple sclerosis.

Reduced Disability Progression, Adverse Events Top Considerations When Selecting Multiple Sclerosis Therapy

Reduced Disability Progression, Adverse Events Top Considerations When Selecting Multiple Sclerosis Therapy

A majority of the respondents in both groups identified reduced disability progression as a priority.

Gait in Multiple Sclerosis Improved With Dalfampridine Plus Physical Therapy

Gait in Multiple Sclerosis Improved With Dalfampridine Plus Physical Therapy

A combination of dalfampridine extended-release and physical therapy (PT) has shown efficacy for improving gait in people with multiple sclerosis

Medical Cannabis Shows Promise in Treating Symptoms of Multiple Sclerosis

Medical Cannabis Shows Promise in Treating Symptoms of Multiple Sclerosis

Differing formulations and ratios of the subjects' medical cannabis regimens have been accounted for, though further information about ratios of CBD and TCH are subject to change due to continued ongoing research.

Multiple Sclerosis Pain Common Disruptive Factor in Everyday Activities

Multiple Sclerosis Pain Common Disruptive Factor in Everyday Activities

Pain in patients with multiple sclerosis may affect their daily functioning regardless of disease severity.

Dimethyl Fumarate Not Associated With Greater Pain vs Other DMTs in Relapsing-Remitting MS

Dimethyl Fumarate Not Associated With Greater Pain vs Other DMTs in Relapsing-Remitting MS

Investigators assessed the effect of disease-modifying treatments on pain in patients with relapsing-remitting multiple sclerosis.

Skin Tone, Race May Be Associated With Multiple Sclerosis Diagnosis

Skin Tone, Race May Be Associated With Multiple Sclerosis Diagnosis

The MS and monophasic ADS groups were compared using quantified melanin measurements via the DSM II Colorimeter; self-reported skin tones of fair, medium, olive, or dark; a self-reported race; and skin tone, which was self-reported using 10 numerical panels of color.

Proposed Protocol Taps Occupational Therapist for Assistance With MS Medication Adherence

Proposed Protocol Taps Occupational Therapist for Assistance With MS Medication Adherence

The protocol authors propose a more objective method of managing medication adherence through a profile performed by an occupational therapist.

Optimized Urinalysis Reflex Reduces Urine Culture Orders in MS

Optimized Urinalysis Reflex Reduces Urine Culture Orders in MS

Due to the increased risk for urinary tract infections (UTIs) in people with MS and similar CNS demyelinating diseases, as well as the tendency of UTIs to trigger more MS flares, the affected population are subject to a large number of unneeded antibiotic prescriptions and asymptomatic bacteriuria treatments.

Certain Comorbidities More Common in People With Multiple Sclerosis

Certain Comorbidities More Common in People With Multiple Sclerosis

The study researchers examined data from the US database of the IMS Health Real World Data Adjudicated Claims between 2011 and 2015.

Tuberculosis Common in MS Treated With Immunosuppressive Agents

Tuberculosis Common in MS Treated With Immunosuppressive Agents

Immunotherapy in multiple sclerosis may increase the risk for conversion from latent to active tuberculosis infection.

Ozanimod Superior to Interferon for Relapsing Multiple Sclerosis

Ozanimod Superior to Interferon for Relapsing Multiple Sclerosis

This study analyzed results from SUNBEAM (ClinicalTrials.gov Identifier: NCT02294058) and RADIANCE (ClinicalTrials.gov Identifier: NCT01628393), 2 double-blind, randomized, phase 3 trials.

Ocrelizumab May Improve Cognition in Patients At Risk for Progressive Multiple Sclerosis

Ocrelizumab May Improve Cognition in Patients At Risk for Progressive Multiple Sclerosis

Cognitive impairment is common in patients with multiple sclerosis (MS) and considerably impacts quality of life.

Alemtuzumab Reduces MRI Disease Activity, Brain Volume Loss in Relapsing-Remitting MS

Alemtuzumab Reduces MRI Disease Activity, Brain Volume Loss in Relapsing-Remitting MS

Alemtuzumab is associated with reduced magnetic resonance imaging disease activity and the slowing of brain volume loss over 7 years in patients with relapsing-remitting multiple sclerosis.

Fingolimod Improves Multiple Sclerosis Outcomes After Previous DMT Failure

Fingolimod Improves Multiple Sclerosis Outcomes After Previous DMT Failure

Brain volume loss was smaller for all groups after treatment with fingolimod.

Ublituximab Associated With Significant Reduction in MS Disease Activity, Focal Lesions

Ublituximab Associated With Significant Reduction in MS Disease Activity, Focal Lesions

TG1101-RMS201 was a multicenter, placebo-controlled, phase 2, 52-week study designed to evaluate the optimal infusion and safety of ublituximab for relapsing multiple sclerosis.

Long-Term Teriflunomide for MS Not Associated With Grade 3 Lymphopenia

Long-Term Teriflunomide for MS Not Associated With Grade 3 Lymphopenia

Analysis of yearly lymphocyte counts showed a declining occurrence of all grades of lymphopenia over time, and by year 9, subjects exhibited no cases of lymphopenia.

Sign Up for Free e-newsletters



CME Focus